727 FinancePANews October 21 news, according to an official OpenAI announcement, OpenAI has acquired Orchestra Bio, a drug R&D collaboration platform. The platform helps biopharmaceutical teams coordinate complex drug development processes, allowing scientists and project leads to delegate the monitoring and tracking of research and trials to AI agents. OpenAI stated that it will integrate Orchestra's team and technology with Rosalind, its life sciences research AI model and tool, to help new therapies reach patients faster.
OpenAI acquires drug R&D collaboration platform Orchestra Bio
Похожие новости
Финансирование недели | Kalshi завершает раунд G на $1 млрд, возглавляемый Sequoia Capital и Wellington Management.
Kalshi завершила раунд финансирования Series G на сумму $1 млрд, достигнув постденежной оценки в $40 млрд, что почти вдвое превышает оценку в $22 млрд в мае это...